SCHEMBL1471037

SCHEMBL1471037

COC(=O)c1cccc(CNCCNc2ccccc2OC(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.49
HTR1A P08908 4/20 0.46
SLC7A5 Q01650 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
CYP4F2 P78329 2/20 0.44
CYP4A11 Q02928 2/20 0.44
SENP1 Q9P0U3 1/20 0.44
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471014 0.85 HTR1A (0.43) HTR1AHDAC3HDAC4HDAC1HDAC7
SCHEMBL1471545 0.84 HTR1A (0.56) HTR1AMAPTRAB9AMEN1KMT2A
SCHEMBL1470745 0.83 HTR1A (0.58) HTR1AMAPTRAB9AMEN1KMT2A
SCHEMBL1471165 0.83 HTR1A (0.58) HTR1AMAPTRAB9AMEN1KMT2A
SCHEMBL1471318 0.81 HTR1A (0.47) HTR1ARAB9AALDH1A1NPSR1NPC1
SCHEMBL1470920 0.81 MEN1 (0.49) HTR1AMEN1KMT2A
SCHEMBL15761754 0.78 HIF1A (0.58) HIF1ASLC7A5LOXL2HDAC1HDAC8
SCHEMBL1470936 0.78 HTR1A (0.56) HTR1AMAPTRAB9AMEN1KMT2A
SCHEMBL21579366 0.75 LOXL2 (0.70) HIF1ASLC7A5LOXL2HDAC1CYP4F2
SCHEMBL21089603 0.75 HIF1A (0.61) HIF1ASLC7A5LOXL2CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20080009521-A1 Aryl Piperidine Amides HUANG CHARLES Q 2008-01-10 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
EP-1660472-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
WO-2005021525-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-10 WO disclosed
US-20050049239-A1 Aryl piperidine amides JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009521-A1 Aryl Piperidine Amides BDNF, NTRK2, OPRL1 HIF1A 766/4885HTR1A 286/4885SLC7A5 756/4885
US-20050049239-A1 Aryl piperidine amides BDNF, NTRK2, OPRL1 HIF1A 766/4885HTR1A 286/4885SLC7A5 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.